Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats

Toxicology and Applied Pharmacology

Volumn 242, Issue 1, 2010, Pages 38-46

  Zordoky, Beshay N M ^a   Anwar Mohamed, Anwar ^a   Aboutabl, Mona E ^a   El Kadi, Ayman O S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Arachidonic acid; Cardiotoxicity; Cytochrome P450; Doxorubicin; Epoxide Hydrolase

Indexed keywords

14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; CYTOCHROME P450 2J3; CYTOCHROME P450 4A3; CYTOCHROME P450 4F1; CYTOCHROME P450 4F4; CYTOCHROME P450 C11; DOXORUBICIN; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE 2; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARACHIDONIC ACID METABOLISM; ARTICLE; CARDIOTOXICITY; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; HEART PROTECTION; MALE; MICROSOME; NONHUMAN; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ARACHIDONIC ACID; CARDIOMEGALY; CYTOCHROME P-450 ENZYME SYSTEM; DOXORUBICIN; EPOXIDE HYDROLASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEART DISEASES; HYDROXYEICOSATETRAENOIC ACIDS; ISOENZYMES; L-LACTATE DEHYDROGENASE; MALE; MICROSOMES; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 70449529313     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.09.012     Document Type: Article

References (47)

1. Ai D., Pang W., Li N., Xu M., Jones P.D., Yang J., Zhang Y., Chiamvimonvat N., Shyy J.Y., Hammock B.D., and Zhu Y. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 564-569
2. Baldwin S.J., Bramhall J.L., Ashby C.A., Yue L., Murdock P.R., Hood S.R., Ayrton A.D., and Clarke S.E. Cytochrome P450 gene induction in rats ex vivo assessed by quantitative real-time reverse transcriptase-polymerase chain reaction (TaqMan). Drug Metab. Dispos. 34 (2006) 1063-1069
3. Barakat M.M., El-Kadi A.O., and du Souich P. L-NAME prevents in vivo the inactivation but not the down-regulation of hepatic cytochrome P450 caused by an acute inflammatory reaction. Life Sci. 69 (2001) 1559-1571
4. Bleicher K.B., Pippert T.R., Glaab W.E., Skopek T.R., Sina J.F., and Umbenhauer D.R. Use of real-time gene-specific polymerase chain reaction to measure RNA expression of three family members of rat cytochrome P450 4A. J. Biochem. Mol. Toxicol. 15 (2001) 133-142
5. Chabova V.C., Kramer H.J., Vaneckova I., Vernerova Z., Eis V., Tesar V., Skaroupkova P., Thumova M., Schejbalova S., Huskova Z., Vanourkova Z., Kolsky A., Imig J.D., and Cervenka L. Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vascul. Pharmacol. 47 (2007) 145-159
6. Chen S., Garami M., and Gardner D.G. Doxorubicin selectively inhibits brain versus atrial natriuretic peptide gene expression in cultured neonatal rat myocytes. Hypertension 34 (1999) 1223-1231
7. Choudhary D., Jansson I., Stoilov I., Sarfarazi M., and Schenkman J.B. Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab. Dispos. 32 (2004) 840-847
8. Christiansen S., and Autschbach R. Doxorubicin in experimental and clinical heart failure. Eur. J. Cardiothorac. Surg. 30 (2006) 611-616
9. Cigremis Y., Parlakpinar H., Polat A., Colak C., Ozturk F., Sahna E., Ermis N., and Acet A. Beneficial role of aminoguanidine on acute cardiomyopathy related to doxorubicin-treatment. Mol. Cell. Biochem. 285 (2006) 149-154
10. Gharavi N., and El-Kadi A.O. tert-Butylhydroquinone is a novel aryl hydrocarbon receptor ligand. Drug Metab. Dispos. 33 (2005) 365-372
11. Hirasawa F., Kawagoe M., Arany S., Koizumi Y., Ueno Y., and Sugiyama T. Styrene monomer primarily induces CYP2B1 mRNA in rat liver. Xenobiotica 35 (2005) 1089-1099
12. Hirotani S., Otsu K., Nishida K., Higuchi Y., Morita T., Nakayama H., Yamaguchi O., Mano T., Matsumura Y., Ueno H., Tada M., and Hori M. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 105 (2002) 509-515
13. Hydock D.S., Lien C.Y., Schneider C.M., and Hayward R. Effects of voluntary wheel running on cardiac function and myosin heavy chain in chemically gonadectomized rats. Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H3254-3264
14. Imig J.D., Zhao X., Capdevila J.H., Morisseau C., and Hammock B.D. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39 (2002) 690-694
15. Iqbal M., Dubey K., Anwer T., Ashish A., and Pillai K.K. Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol. Rep. 60 (2008) 382-390
16. Jiang J.G., Ning Y.G., Chen C., Ma D., Liu Z.J., Yang S., Zhou J., Xiao X., Zhang X.A., Edin M.L., Card J.W., Wang J., Zeldin D.C., and Wang D.W. Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res. 67 (2007) 6665-6674
17. Kalsotra A., Anakk S., Boehme C.L., and Strobel H.W. Sexual dimorphism and tissue specificity in the expression of CYP4F forms in Sprague Dawley rats. Drug Metab. Dispos. 30 (2002) 1022-1028
18. Kimes B.W., and Brandt B.L. Properties of a clonal muscle cell line from rat heart. Exp. Cell Res. 98 (1976) 367-381
19. Korashy H.M., and El-Kadi A.O. Differential effects of mercury, lead and copper on the constitutive and inducible expression of aryl hydrocarbon receptor (AHR)-regulated genes in cultured hepatoma Hepa 1c1c7 cells. Toxicology 201 (2004) 153-172
20. Laethem R.M., Balazy M., Falck J.R., Laethem C.L., and Koop D.R. Formation of 19(S)-, 19(R)-, and 18(R)-hydroxyeicosatetraenoic acids by alcohol-inducible cytochrome P450 2E1. J. Biol. Chem. 268 (1993) 12912-12918
21. Laethem R.M., Halpert J.R., and Koop D.R. Epoxidation of arachidonic acid as an active-site probe of cytochrome P-450 2B isoforms. Biochim. Biophys. Acta. 1206 (1994) 42-48
22. Li S., EM, and Yu B. Adriamycin induces myocardium apoptosis through activation of nuclear factor kappaB in rat. Mol. Biol. Rep. 35 (2008) 489-494
23. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
24. Loch D., Hoey A., Morisseau C., Hammock B.O., and Brown L. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem. Biophys. 47 (2007) 87-98
25. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
26. Lv X., Wan J., Yang J., Cheng H., Li Y., Ao Y., and Peng R. Cytochrome P450 omega-hydroxylase inhibition reduces cardiomyocyte apoptosis via activation of ERK1/2 signaling in rat myocardial ischemia-reperfusion. Eur. J. Pharmacol. 596 (2008) 118-126
27. Minuz P., Jiang H., Fava C., Turolo L., Tacconelli S., Ricci M., Patrignani P., Morganti A., Lechi A., and McGiff J.C. Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. Hypertension 51 (2008) 1379-1385
28. Mitra M.S., Donthamsetty S., White B., Latendresse J.R., and Mehendale H.M. Mechanism of protection of moderately diet restricted rats against doxorubicin-induced acute cardiotoxicity. Toxicol. Appl. Pharmacol. 225 (2007) 90-101
29. Monti J., Fischer J., Paskas S., Heinig M., Schulz H., Gosele C., Heuser A., Fischer R., Schmidt C., Schirdewan A., Gross V., Hummel O., Maatz H., Patone G., Saar K., Vingron M., Weldon S.M., Lindpaintner K., Hammock B.D., Rohde K., Dietz R., Cook S.A., Schunck W.H., Luft F.C., and Hubner N. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat. Genet. 40 (2008) 529-537
30. Nakamura T., Ueda Y., Juan Y., Katsuda S., Takahashi H., and Koh E. Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: in vivo study. Circulation 102 (2000) 572-578
31. Ng V.Y., Huang Y., Reddy L.M., Falck J.R., Lin E.T., and Kroetz D.L. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha. Drug Metab. Dispos. 35 (2007) 1126-1134
32. Nithipatikom K., Grall A.J., Holmes B.B., Harder D.R., Falck J.R., and Campbell W.B. Liquid chromatographic-electrospray ionization-mass spectrometric analysis of cytochrome P450 metabolites of arachidonic acid. Anal. Biochem. 298 (2001) 327-336
33. Outomuro D., Grana D.R., Azzato F., and Milei J. Adriamycin-induced myocardial toxicity: new solutions for an old problem?. Int. J. Cardiol. 117 (2007) 6-15
34. Rahman A., Alam M., Rao S., Cai L., Clark L.T., Shafiq S., and Siddiqui M.A. Differential effects of doxorubicin on atrial natriuretic peptide expression in vivo and in vitro. Biol. Res. 34 (2001) 195-206
35. Rollin R., Mediero A., Fernandez-Cruz A., and Fernandez-Durango R. Downregulation of the atrial natriuretic peptide/natriuretic peptide receptor-C system in the early stages of diabetic retinopathy in the rat. Mol. Vis. 11 (2005) 216-224
36. Roman R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82 (2002) 131-185
37. Seubert J.M., Zeldin D.C., Nithipatikom K., and Gross G.J. Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat. 82 (2007) 50-59
38. Takemura G., and Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog. Cardiovasc. Dis. 49 (2007) 330-352
39. Ueno M., Kakinuma Y., Yuhki K., Murakoshi N., Iemitsu M., Miyauchi T., and Yamaguchi I. Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J. Pharmacol. Sci. 101 (2006) 151-158
40. Wang S., Hartley D.P., Ciccotto S.L., Vincent S.H., Franklin R.B., and Kim M.S. Induction of hepatic phase II drug-metabolizing enzymes by 1,7-phenanthroline in rats is accompanied by induction of MRP3. Drug Metab. Dispos. 31 (2003) 773-775
41. Xu D., Li N., He Y., Timofeyev V., Lu L., Tsai H.J., Kim I.H., Tuteja D., Mateo R.K., Singapuri A., Davis B.B., Low R., Hammock B.D., and Chiamvimonvat N. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 18733-18738
42. Yousif M.H., Benter I.F., and Roman R.J. Cytochrome P450 metabolites of arachidonic acid play a role in the enhanced cardiac dysfunction in diabetic rats following ischaemic reperfusion injury. Auton. Autacoid. Pharmacol. 29 (2009) 33-41
43. Zhang Y., El-Sikhry H., Chaudhary K., Batchu S.N., Shayeganpour A., Jukar T.O., Bradbury J.A., Graves J.P., Degraff L.M., Myers P.H., Rouse D.C., Foley J., Nyska A., Zeldin D.C., and Seubert J.M. Overexpression of CYP2J2 provides protection against doxorubicin induced cardiotoxicity. Am. J. Physiol. Heart Circ. Physiol. (2009)
44. Zhao X., Quigley J.E., Yuan J., Wang M.H., Zhou Y., and Imig J.D. PPAR-alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H2187-2195
45. Zordoky B.N., Aboutabl M.E., and El-Kadi A.O. Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol-induced cardiac hypertrophy in rats. Drug Metab. Dispos. 36 (2008) 2277-2286
46. Zordoky B.N., and El-Kadi A.O. Induction of several cytochrome P450 genes by doxorubicin in H9c2 cells. Vascul. Pharmacol. 49 (2008) 166-172
47. Zordoky B.N., and El-Kadi A.O. Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure. Curr. Drug Metab. 9 (2008) 122-128